Eventide Asset Management - Q3 2019 holdings

$3.03 Billion is the total value of Eventide Asset Management's 124 reported holdings in Q3 2019. The portfolio turnover from Q2 2019 to Q3 2019 was 0.0% .

 Value Shares↓ Weighting
ASND  ASCENDIS PHARMA A Ssponsored adr$163,614,000
-16.4%
1,698,6480.0%5.41%
-9.1%
ZGNX  ZOGENIX INC$113,766,000
-16.2%
2,841,3000.0%3.76%
-8.9%
TWLO  TWILIO INCcl a$90,937,000
-19.4%
827,0000.0%3.00%
-12.3%
ROP  ROPER TECHNOLOGIES INC$76,312,000
-2.6%
214,0000.0%2.52%
+5.8%
WCN  WASTE CONNECTIONS INC$73,968,000
-3.7%
804,0000.0%2.44%
+4.6%
LOW  LOWES COS INC$63,975,000
+9.0%
581,8000.0%2.11%
+18.4%
PANW  PALO ALTO NETWORKS INC$58,499,000
+0.0%
287,0000.0%1.93%
+8.7%
LRCX  LAM RESEARCH CORP$52,462,000
+23.0%
227,0000.0%1.73%
+33.7%
SPLK  SPLUNK INC$50,444,000
-6.3%
428,0000.0%1.67%
+1.9%
EXAS  EXACT SCIENCES CORP$44,733,000
-23.4%
495,0000.0%1.48%
-16.8%
BPMC  BLUEPRINT MEDICINES CORP$33,943,000
-22.1%
462,0000.0%1.12%
-15.3%
IPHI  INPHI CORP$33,883,000
+21.9%
555,0000.0%1.12%
+32.5%
MYOK  MYOKARDIA INC$32,385,000
+4.0%
621,0000.0%1.07%
+13.0%
NBIX  NEUROCRINE BIOSCIENCES INC$31,809,000
+6.7%
353,0000.0%1.05%
+16.0%
MGA  MAGNA INTL INC$31,305,000
+7.3%
587,0000.0%1.03%
+16.6%
CTAS  CINTAS CORP$29,759,000
+13.0%
111,0000.0%0.98%
+22.7%
PAYC  PAYCOM SOFTWARE INC$29,538,000
-7.6%
141,0000.0%0.98%
+0.4%
PEGI  PATTERN ENERGY GROUP INCcl a$28,901,000
+16.6%
1,073,2000.0%0.96%
+26.8%
IDXX  IDEXX LABS INC$27,982,000
-1.2%
102,9000.0%0.92%
+7.4%
ANET  ARISTA NETWORKS INC$27,954,000
-8.0%
117,0000.0%0.92%
+0.1%
COLL  COLLEGIUM PHARMACEUTICAL INC$27,873,000
-12.7%
2,427,9760.0%0.92%
-5.1%
GLPG  GALAPAGOS NVspon adr$26,410,000
+18.4%
173,0000.0%0.87%
+28.8%
GBT  GLOBAL BLOOD THERAPEUTICS IN$25,958,000
-7.8%
535,0000.0%0.86%
+0.4%
IAA  IAA INC$25,455,000
+7.6%
610,0000.0%0.84%
+17.0%
VRNS  VARONIS SYS INC$25,108,000
-3.5%
420,0000.0%0.83%
+4.9%
VCYT  VERACYTE INC$22,320,000
-15.8%
930,0000.0%0.74%
-8.6%
LEA  LEAR CORP$21,694,000
-15.3%
184,0000.0%0.72%
-8.0%
PFPT  PROOFPOINT INC$20,390,000
+7.3%
158,0000.0%0.67%
+16.6%
GWPH  GW PHARMACEUTICALS PLCads$20,130,000
-33.3%
175,0000.0%0.66%
-27.5%
RARX  RA PHARMACEUTICALS INC$17,572,000
-21.3%
743,0000.0%0.58%
-14.4%
MNTA  MOMENTA PHARMACEUTICALS INC$16,019,000
+4.1%
1,236,0000.0%0.53%
+13.0%
FOLD  AMICUS THERAPEUTICS INC$15,639,000
-35.7%
1,950,0000.0%0.52%
-30.1%
KAR  KAR AUCTION SVCS INC$14,976,000
-1.8%
610,0000.0%0.50%
+6.7%
OKTA  OKTA INCcl a$14,769,000
-20.3%
150,0000.0%0.49%
-13.3%
BOLD  AUDENTES THERAPEUTICS INC$14,017,000
-25.8%
499,0000.0%0.46%
-19.3%
ISRG  INTUITIVE SURGICAL INC$13,498,000
+2.9%
25,0000.0%0.45%
+11.8%
XENE  XENON PHARMACEUTICALS INC$11,480,000
-8.6%
1,274,1000.0%0.38%
-0.8%
XNCR  XENCOR INC$10,119,000
-17.6%
300,0000.0%0.33%
-10.5%
ARYAU  ARYA SCIENCES ACQUISITION COunit 10/04/2023$8,768,000
+2.5%
800,0000.0%0.29%
+11.5%
HSACU  HEALTH SCIENCES ACQUSTN CORPunit 04/01/2024$7,296,000
+1.2%
680,0000.0%0.24%
+10.0%
THOR  SYNTHORX INC$6,508,000
+20.4%
400,0000.0%0.22%
+31.1%
FENC  FENNEC PHARMACEUTICALS INC$3,463,000
+20.2%
720,0000.0%0.11%
+29.5%
ORTX  ORCHARD THERAPEUTICS PLCads$3,208,000
-15.1%
270,0000.0%0.11%
-7.8%
CBIO  CATALYST BIOSCIENCES INC$2,273,000
-33.4%
462,8520.0%0.08%
-27.9%
WM  WASTE MGMT INC DEL$2,243,000
-0.3%
19,5000.0%0.07%
+8.8%
TERP  TERRAFORM PWR INC$1,691,000
+27.4%
92,8000.0%0.06%
+40.0%
MLHR  MILLER HERMAN INC$982,000
+3.2%
21,3000.0%0.03%
+10.3%
ABB  ABB LTDsponsored adr$315,000
-1.6%
16,0000.0%0.01%0.0%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2019-11-21
Signatures

The EDGAR filing(s) were signed by:

About Eventide Asset Management

Eventide Asset Management is a Boston-based investment firm that specializes in providing investment solutions to investors who are looking for long-term growth opportunities. The company was founded in 2008 by a group of experienced investment professionals who shared a common vision of creating a firm that would focus on investing in companies that are making a positive impact on society.

The company's investment philosophy is based on the belief that companies that are making a positive impact on society are more likely to be successful in the long run. Eventide's investment team conducts extensive research to identify companies that are aligned with this philosophy and have the potential to deliver strong returns over the long term.

The company's investment strategies are managed by a team of experienced professionals, including CEO Robin John, COO Finny Kuruvilla, and Chief Investment Officer, Dr. Finny Kuruvilla. The team has a proven track record of delivering strong returns to investors, and their investment strategies have been recognized by industry experts.

Eventide Asset Management offers a range of investment solutions, including mutual funds, separately managed accounts, and exchange-traded funds (ETFs). The company's funds are available to individual investors, financial advisors, and institutional investors.

Overall, Eventide Asset Management is a reputable investment firm that has a strong focus on investing in companies that are making a positive impact on society. The company's experienced investment team and proven track record make it a compelling option for investors who are looking for long-term growth opportunities.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
LOWES COS INC40Q3 20233.2%
PALO ALTO NETWORKS INC40Q3 20233.6%
ASML HOLDINGS NV40Q3 20231.9%
NEUROCRINE BIOSCIENCES INC40Q3 20231.1%
REPLIGEN CORP40Q3 20230.5%
VERACYTE INC38Q3 20231.5%
LAM RESEARCH CORP35Q3 20233.4%
XPO LOGISTICS INC34Q1 20233.8%
COLLEGIUM PHARMACEUTICAL INC34Q3 20232.6%
MAGNA INTL INC33Q4 20212.5%

View Eventide Asset Management's complete holdings history.

Latest significant ownerships (13-D/G)
Eventide Asset Management Q3 2019 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Cogent Biosciences, Inc.February 14, 20232,589,7783.7%
ESSA Pharma Inc.Sold outFebruary 14, 202300.0%
Freeline Therapeutics Holdings plcFebruary 14, 20235,920,7659.1%
KnowBe4, Inc.Sold outFebruary 14, 202300.0%
Praxis Precision Medicines, Inc.February 14, 20233,518,0627.5%
Prometheus Biosciences, Inc.February 14, 20231,032,9382.2%
SUTRO BIOPHARMA, INC.Sold outFebruary 14, 202300.0%
Vital Farms, Inc.Sold outFebruary 14, 202300.0%
Zymeworks Inc.Sold outFebruary 14, 202300.0%
Entasis Therapeutics Holdings Inc.February 14, 2022590,6021.2%

View Eventide Asset Management's complete significant-ownership history.

Latest filings
TypeFiled
13F-HR/A2024-02-20
13F-HR2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14

View Eventide Asset Management's complete filings history.

Compare quarters

Export Eventide Asset Management's holdings